Axsome Therapeutics Inc. (AXSM) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Axsome Therapeutics Inc. (AXSM)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

84.66

-4.61 (-5.16%)

At close: Jan 14, 2025, 3:59 PM

84.85

0.22%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	84.89
Market Cap	4.10B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-6.58
PE Ratio (ttm)	-12.87
Forward PE	n/a
Analyst	Buy

Ask	86
Volume	562,933
Avg. Volume (20D)	627,234
Open	88.72
Previous Close	89.27
Day's Range	84.64 - 89.96
52-Week Range	64.11 - 105.00
Beta	undefined

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 19, 2015

Employees 607

Stock Exchange NASDAQ

Ticker Symbol AXSM

Website https://www.axsome.com

Analyst Forecast

According to 14 analyst ratings, the average rating for AXSM stock is "Buy." The 12-month stock price forecast is $121.5, which is an increase of 43.52% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Axsome Therapeutics Inc. is scheduled to release its earnings on Feb 18, 2025, before market opens.
Analysts project revenue of $117.89M, reflecting a 64.81% YoY growth and earnings per share of -1.03, making a 41.10% increase YoY.

Why Price Moved

1 day ago · Source New

+11.52%

Axsome Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

2 months ago · Source

+9.35%

Axsome Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and provided updates regarding the cash on its balance sheet. Also, Needham reiterated a Buy rating on the stock.

News

21 hours ago · zacks.com

Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

2 weeks ago · seekingalpha.com

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AX...

2 weeks ago · benzinga.com

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

On Monday, Axsome Therapeutics, Inc. AXSM released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation.

2 weeks ago · benzinga.com

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling more than 50 points on Monday.

2 weeks ago · reuters.com

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Axsome Therapeutics said on Monday its experimental treatment for the Alzheimer's disease-related agitation met the main goal of a late-stage trial.

1 month ago · zacks.com

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

1 month ago · seekingalpha.com

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial...

1 month ago · benzinga.com

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

On Tuesday, Axsome Therapeutics Inc AXSM said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial.

2 months ago · zacks.com

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.

2 months ago · seekingalpha.com

Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Ni...

2 months ago · seekingalpha.com

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axso...

2 months ago · zacks.com

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.32 per share a year ago.

2 months ago · zacks.com

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

2 months ago · zacks.com

Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · fool.com

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Yes, bargains can still be found in the stock market.